- Experts are calling for mandatory isolation of those being infected with flu
- Pacific Edge to hold its Annual Meeting in July
- TruScreen Group provides an update on its performance in FY22
With the rising number of flu cases across New Zealand, experts are calling for mandatory self-isolation for flu-infected people as hospitals are battling to meet immense demand.
Stay-at-home orders will help reduce pressure on hospitals that currently are being impacted by staff shortages coupled with a bad winter illness season and the COVID-19 pandemic.
Also, the reintroduction of compulsory masks in schools would help limit the flu spread across New Zealand, and lessons of the ongoing pandemic should be applied across the winter months as the nation’s health system hospitals struggle to meet the immense demand arising from COVID-19 and influenza infections, cites an epidemiologist from Otago University.
With this overview, let us now look at the four NZX-listed healthcare stocks.
Source: © Ipopba | Megapixl.com
Having expertise in innovative bladder cancer technology, Pacific Edge Limited will conduct its Annual Shareholder Meeting on 28 July, which will be held both in person as well as online.
It intends to pass resolutions pertaining to the election and re-election of its directors as well as authorising its Board to fix PwC, its auditor's fees, and expenses for the ensuing year.
At the time of writing on 30 June, PEB was up 2.90% at NZ$0.710.
Rua Bioscience Limited (NZX:RUA)
Rua Bioscience Limited, a medicinal cannabis products company, has recently announced that it was on track to export its consignment to Germany by year end.
The Company has revealed that it had received its narcotic licence through Nimbus Health for distributing and marketing its first medicinal cannabis product for the German market, making it the first Kiwi medicinal cannabis company to take such a step.
Moreover, later this year, RUA will disclose further expansion plans as it finalises distribution agreements across Europe.
At the time of writing on 30 June, RUA was jumping 8.20% at NZ$0.330.
TruScreen Group Limited is a medical device company. Last month, TRU published an update on its solid progress made in FY22.
The business across the China market continued to strengthen with remarkable revenue growth and outstanding clinical trial results. Further, TRU recorded its first sales in Eastern Europe and has received product registration in five countries. Also, it has partnered with a local hospital in Vietnam and a medical device financing company in Mexico, thereby expanding its medical product range to reach the broader market.
At the time of writing on 30 June, TRU was down 3.85% at NZ$0.050.
Oceania Healthcare Limited is a leading operator of retirement villages and an aged care services provider.
Today, the Company has announced the implementation of SLL, i.e., a Sustainability-Linked Loan worth NZ$500 million for a period of five years.
The said development will support OCA’s commitment to sustainable growth and outlines its seriousness about environmental and social sustainability targets. Further, it has created a Framework for the same, outlining its outlook towards sustainable finance instruments as well as regulations under which the Company plans to issue and manage SLLs.
At the time of writing on 30 June, OCA was trading flat at NZ$0.950.
NZ health authorities are leaving no stone unturned to protect health and ensure the safety of its people during these challenging times.